To order chemicals, medical devices, or other restricted products, please provide identification that includes your business name and shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of identification are:
- • Issued document with your organization's Federal Tax ID Number
- • Government issued document with your organization's Resale Tax ID Number
- • Any other Government ID that includes the business name and address
Avantor will not lift restrictions for residential shipping addresses.
Spécifications
- Assay duration:Multiple steps
- Assay Type:Indirect
- Conjugate ELISA:Unconjugated
- Format:Pre-coated
- Host:Goat
- Primary antibody reactivity:Human
- Target protein:Varicella-Zoster virus (VZV) gE protein
- Size:96 tests
Spécifications
À propos de cet article
This kit is developed for serologic test for human IgA titer of Anti-VZV gE antibody in serum/plasma or purified human antibody (monoclonal and polyclonal) in vitro. Antibodies of IgM and IgA class are a sign of an active infection (primary infection and reactivation) and disappear during convalescence. In some cases they can persist for several months.
These kits were tested to bind to monoclonal antibodies in IgA format (N42Z57) or human sera
- Recommendations - customers who intend to use this kit to generate quantitative curves are suggested to consider the monoclonal antibodies to generate the reference curve: Recombinant Human Anti-Varicella-Zoster virus (VZV) gE IgA Antibody (N42Z57)
The human Anti-Varicella-Zoster virus (VZV) is associated with two distinct diseases: childhood chickenpox (varicella) and shingles (zoster). After a primary infection, VZV remains latent in the sensory ganglia throughout the person’s lifetime and may reactivate to cause shingles. VZV DNA encodes seven glycoproteins (gB, gC, gE, gH, gI, gK, and gL) and gE is a dominant antigen of an approved vaccine (RZV, Shingrix, GSK). A rapid and effective assay kit detecting the levels of anti-VZV gE in human serum can facilitate research on antibodies produced in response to VZV infection or vaccine (approved or candidate).
Assay principles:
This kit is developed for a standard indirect-ELISA format, providing a rapid detection of anti-Varicella-Zoster virus (VZV) gE human IgA in serum. The kit consists of high-bind detachable 96-well plate pre-coated with gE protein, positive control, negative control, an HRP-Anti-Human IgA secondary antibody, TMB and dilution/wash/stop buffer.
Use protocol (Four simple steps):
1. Detach wells from plate based on your samples and keep at room temperature. Dilute your samples, positive and negative controls in sample dilution buffer and add them to wells (0.1 ml/well). Incubate at 37 °C for 1 hour or room temperature for 1.5 hour. Wash wells four times by wash solution (0.3 ml/well).
2. Dilute the Secondary antibody HRP-Anti-Human IgA by wash solution and add to each well (0.1 ml/well). Incubate at room temperature for 0.5 to 1 hour. Avoid light by foil. Wash wells as mentioned.
3. Add TMB to each well (0.1 ml/well) and incubate at room temperature for 10 to 30 minutes.
4. Stop the substrate reaction by adding stop solution (0.1 ml/well). Absorbance (OD) is calculated as the absorbance at 450 nm. The OD Value reflects the amount of antibody bound.
For research use only.